Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EACR 2012 /
The changing field of drug development

7th - 10th Jul 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 16.07.12
Views: 3666

Dr Jonathan Yingling – Oncology Drug Discovery, Eli Lilly

Talking to ecancer at EACR 22, Dr Jonathan Yingling discusses the paradigm of drug discovery and development.


The process of drug development involves identifying targets from cancer biology and then development of molecular target therapeutics. Recently, importance shifted from creating drugs with the general population of patients in mind to identifing the optimal patient population.


The changing focus from general to specific patient populations is currently a key issue in drug development, as well as the changes in the regulatory landscape of pharmaceutical development. Dr Yingling also discusses the importance and influence of biomarkers in current trials and the very basic, molecular level, starting point for all drug research.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation